» Articles » PMID: 16774942

Novel Polymorphisms in the SUV39H2 Histone Methyltransferase and the Risk of Lung Cancer

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2006 Jun 16
PMID 16774942
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Histone H3 lysine 9 (H3-K9) methylation and DNA methylation are important features of mammalian heterochromatin. Suppressor of variegation 3-9 homolog 2 (SUV39H2) is the histone methyltransferase that is required to methylate H3-K9, leading to transcriptional repression or silencing of target genes. In this study, we investigated the association of SUV39H2 polymorphisms and the risk of lung cancer. From the results of PCR direct sequencing, eight single nucleotide polymorphisms (SNPs) of SUV39H2 were identified in Korean population. In a hospital-based study of 346 lung cancer patients and 423 healthy controls, a novel SNP in the 3'-UTR of SUV39H2 (1624 G-->C) was associated with a statistically significant increase in lung cancer risk. Compared to the G/G genotype, genotypes with 1624C allele (G/C + C/C) significantly increased the susceptibility to lung cancer with adjusted odds ratio (AOR) of 2.63 (95% confidence interval (CI)= 1.10-6.29) for ever-smokers, especially in the older age group (age >or=55 years). Specifically, the variant genotype of 1624SNP was significantly associated with an increased risk of squamous cell carcinoma (AOR, 3.52; 95% CI = 1.13-9.45) in the older age group, while no significant association was found in patients with other histology. This study provided the first evidence that a novel SUV39H2 polymorphism may be an important predictive marker for lung cancer susceptibility for the smokers.

Citing Articles

Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway.

Sun D, Guo J, Liang W, Chen Y, Wei S, Li A Med Oncol. 2024; 41(2):44.

PMID: 38170382 DOI: 10.1007/s12032-023-02252-x.


Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Cheng Y, He C, Wang M, Ma X, Mo F, Yang S Signal Transduct Target Ther. 2019; 4:62.

PMID: 31871779 PMC: 6915746. DOI: 10.1038/s41392-019-0095-0.


New discoveries of mdig in the epigenetic regulation of cancers.

Zhang Q, Thakur C, Shi J, Sun J, Fu Y, Stemmer P Semin Cancer Biol. 2019; 57:27-35.

PMID: 31276784 PMC: 6844078. DOI: 10.1016/j.semcancer.2019.06.013.


Suppressor of Variegation 3-9 Homolog 2, a Novel Binding Protein of Translationally Controlled Tumor Protein, Regulates Cancer Cell Proliferation.

Kim A, Sung J, Rho S, Kim Y, Yoon K Biomol Ther (Seoul). 2019; 27(2):231-239.

PMID: 30763986 PMC: 6430221. DOI: 10.4062/biomolther.2019.021.


The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.

Li B, Zheng Y, Yang L J Cancer. 2019; 10(3):721-729.

PMID: 30719171 PMC: 6360419. DOI: 10.7150/jca.28254.